|
1
|
Wang XC, Xi RJ, Li Y, Wang DM and Yao YJ:
The species identity of the widely cultivated Ganoderma, ‘G.
lucidum’ (Ling-zhi), in China. PLoS One. 7:e408572012. View Article : Google Scholar
|
|
2
|
Li J, Zhang J, Chen H, Chen X, Lan J and
Liu C: Complete mitochondrial genome of the medicinal mushroom
Ganoderma lucidum. PLoS One. 8:e720382013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shiao MS: Natural products of the
medicinal fungus Ganoderma lucidum: Occurrence, biological
activities, and pharmacological functions. Chem Rec. 3:172–180.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gordan JD, Chay WY, Kelley RK, Ko AH, Choo
SP and Venook AP: And what other medications are you taking? J Clin
Oncol. 29:e288–e291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papadopoulos I, Guo F, Lees S and Ridge M:
An exploration of the meanings and experiences of cancer of Chinese
people living and working in London. Eur J Cancer Care. 16:424–432.
2007. View Article : Google Scholar
|
|
6
|
Sliva D: Ganoderma lucidum (Reishi) in
cancer treatment. Integr Cancer Ther. 2:358–364. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Batra P, Sharma AK and Khajuria R: Probing
Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher
Basidiomycetes): A bitter mushroom with amazing health benefits.
Int J Med Mushrooms. 15:127–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wachtel-Galor S, Yuen J, Buswell JA and
Benzie IFF: Ganoderma lucidum (Lingzhi or Reishi): A Medicinal
MushroomHerbal Medicine: Biomolecular and Clinical Aspects. Benzie
IFF and Wachtel-Galor S: 92nd. CRC Press/Taylor & Francis; Boca
Raton, FL: 2011, http://dx.doi.org/10.1201/b10787 View Article : Google Scholar
|
|
9
|
Xu Z, Chen X, Zhong Z, Chen L and Wang Y:
Ganoderma lucidum polysaccharides: Immunomodulation and potential
anti-tumor activities. Am J Chin Med. 39:15–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shang D, Li Y, Wang C, Wang X, Yu Z and Fu
X: A novel polysaccharide from Se-enriched Ganoderma lucidum
induces apoptosis of human breast cancer cells. Oncol Rep.
25:267–272. 2011.PubMed/NCBI
|
|
11
|
Huang CY, Chen JY, Wu JE, Pu YS, Liu GY,
Pan MH, Huang YT, Huang AM, Hwang CC, Chung SJ, et al: Ling-Zhi
polysaccharides potentiate cytotoxic effects of anticancer drugs
against drug-resistant urothelial carcinoma cells. J Agric Food
Chem. 58:8798–8805. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Zhang L, Yu Y and Cheung PC:
Enhancement of antitumor activities in sulfated and
carboxymethylated polysaccharides of Ganoderma lucidum. J Agric
Food Chem. 57:10565–10572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boh B: Ganoderma lucidum: A potential for
biotechnological production of anti-cancer and immunomodulatory
drugs. Recent Patents Anticancer Drug Discov. 8:255–287. 2013.
View Article : Google Scholar
|
|
14
|
Jin X, Beguerie J Ruiz, Sze DM and Chan
GC: Ganoderma lucidum (Reishi mushroom) for cancer treatment.
Cochrane Database Syst Rev. 6:CD0077312012.
|
|
15
|
Zhang J, Chen JM, Wang XX, Xia YM, Cui SW,
Li J and Ding ZY: Inhibitor or promoter? The performance of
polysaccharides from Ganoderma lucidum on human tumor cells with
different p53 statuses. Food Funct. 7:1872–1875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang Z, Guo YT, Yi YJ, Wang RC, Hu QL and
Xiong XY: Ganoderma lucidum polysaccharides target a Fas/caspase
dependent pathway to induce apoptosis in human colon cancer cells.
Asian Pac J Cancer Prev. 15:3981–3986. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y and Bodmer WF: Analysis of P53
mutations and their expression in 56 colorectal cancer cell lines.
Proc Natl Acad Sci USA. 103:976–981. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nigro JM, Baker SJ, Preisinger AC, Jessup
JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee
P, et al: Mutations in the p53 gene occur in diverse human tumour
types. Nature. 342:705–708. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hainaut P and Hollstein M: p53 and human
cancer: The first ten thousand mutations. Adv Cancer Res.
77:81–137. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mihara M, Erster S, Zaika A, Petrenko O,
Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic
role at the mitochondria. Mol Cell. 11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moll UM, Wolff S, Speidel D and Deppert W:
Transcription-independent pro-apoptotic functions of p53. Curr Opin
Cell Biol. 17:631–636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chipuk JE, Kuwana T, Bouchier-Hayes L,
Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of
Bax by p53 mediates mitochondrial membrane permeabilization and
apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chipuk JE and Green DR: Cytoplasmic p53:
Bax and forward. Cell Cycle. 3:429–431. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boh B, Berovic M, Zhang J and Zhi-Bin L:
Ganoderma lucidum and its pharmaceutically active compounds.
Biotechnol Annu Rev. 13:265–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Xie MY, Wang YX, Nie SP and Li C:
Analysis of the monosaccharide composition of purified
polysaccharides in Ganoderma atrum by capillary gas chromatography.
Phytochem Anal. 20:503–510. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin ZB: Cellular and molecular mechanisms
of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci.
99:144–153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li N, Hu YL, He CX, Hu CJ, Zhou J, Tang GP
and Gao JQ: Preparation, characterisation and anti-tumour activity
of Ganoderma lucidum polysaccharide nanoparticles. J Pharm
Pharmacol. 62:139–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang F, Liu J, Robbins D, Morris K, Sit A,
Liu YY and Zhao Y: Mutant p53 exhibits trivial effects on
mitochondrial functions which can be reactivated by ellipticine in
lymphoma cells. Apoptosis. 16:301–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X, Wilcken R, Joerger AC, Chuckowree
IS, Amin J, Spencer J and Fersht AR: Small molecule induced
reactivation of mutant p53 in cancer cells. Nucleic Acids Res.
41:6034–6044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Selivanova G and Wiman KG: Reactivation of
mutant p53: Molecular mechanisms and therapeutic potential.
Oncogene. 26:2243–2254. 2007. View Article : Google Scholar : PubMed/NCBI
|
